Financials
Financial year 2025
Worth noting
- The team shrank two years in a row.
- Figures corrected afterwards (2023).
Gross margin
€ 2.2 million
▲ 109% vs 2024
Profit
Caution€ -362,888
▼ 250% vs 2024
Debts
Low€ 920,824
▼ 13% vs 2024
VESALE PHARMACEUTICA from Gembloux, company number BE0452282591, closed financial year 2025 with a result of € -362,888 after tax. For that financial year VESALE PHARMACEUTICA recorded a gross margin of € 2.2 million and equity of € 3.1 million. Compared with financial year 2024, the result moved from € 242,636 to € -362,888. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
What happened at VESALE PHARMACEUTICA?
What happened at VESALE PHARMACEUTICA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Aquitania SA stepped down as director. NBB
- MD Consult SA stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 362,888 (▼ 250% vs 2024). Source: NBB ↗
- Jehan Lienart van Lidth de Jeude stepped down as director. NBB
- Nathalie Géruzet stepped down as director. NBB
- Aquitania SA became a director. NBB
- MD Consult SA became a director. NBB
- Rode Ventures SRL stepped down as director. NBB
In short
From € 61,801 loss in 2021 to € 362,888 loss in 2025.
Paid € 40,561 in corporate taxes since 2021.
Best year ever: 2022, with € 340,451 profit.
On average € 784,000 of value added per employee in 2025.
A new publication or filing at VESALE PHARMACEUTICA? We notify you, reason included.
Follow VESALE PHARMACEUTICANeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Nathalie Géruzet
Director
since 2020 · until 2025
Director · represented by Anja Imschoot
Also active at: Ceres Pharmaceuticals, b+pharma Belgium, DGPharma +6 more
since 2025 · until 2031
Director · represented by Mario Debel
Also active at: Ceres Pharmaceuticals, 2PHARMA HOLDING, MD Pharma +5 more
since 2025 · until 2031
Director · represented by Pierre Iweins d'Eechoutte
Also active at: BROUWERIJ-HANDELSMAATSCHAPPIJ, ARTIFREEZE, OP FOODS
since 2019 · until 2025
Vesale Pharma International SA
Managing director · represented by Jehan Lienart van Lidth de Jeude
since 2019 · until 2025
Jehan Lienart van Lidth de Jeude
Director
since 2025 · until 2025
Establishments
Establishment units
Physical locations of this company
Rue Jean Sonet,Isnes 29
5032 Gembloux
Rue Louis Allaert,Noville 9
5310 Eghezée
Active since 12 October 1999
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0452.282.591
- VAT number
- BE 0452.282.591
- Registered office
- Rue Jean Sonet,Isnes 29, 5032 Gembloux
- Names & denominations
- VESALE PHARMACEUTICA · VESALE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 March 1994
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Groothandel in parfumerieën en cosmetica